Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¸°­ÀÛ¿­°¨ÁõÈıºÀÇ Ä¡·á¸¦ À§ÇÑ Àü½ÅÀû Ŭ·Î³ªÁ¦ÆÊÀÇ Åõ¿© ½Ã ȯÀÚÀÇ ÀÓ»óÀû Ư¡¿¡ µû¸¥ È¿´ÉÀÇ Â÷ÀÌ¿¡ °üÇÑ ¿¬±¸

Clinical Features Affecting the Efficacy of Systemic Clonazepam for Management of Burning Mouth Syndrome

´ëÇѱ¸°­³»°úÇÐȸÁö 2012³â 37±Ç 3È£ p.161 ~ 167
¹Îº¸°æ, Á¤À籤, ÃÖÀç°©,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Îº¸°æ ( Min Bo-Kyung ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
Á¤À籤 ( Jung Jae-Kwang ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
ÃÖÀç°© ( Choi Jae-Kap ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç

Abstract

±¸°­ÀÛ¿­°¨ÁõÈıºÀº ±¸°­Á¡¸·ÀÇ ¸¸¼ºÅëÁõ¼º ÀÛ¿­°¨ÀÌ´Ù. ±¸°­ÀÛ¿­°¨ÁõÈıºÀÇ Ä¡·á·Î´Â ¾à¹°Ä¡·á, ½É¸®Ä¡·á°¡ ÀÖ´Ù. °ú°ÅÀÇ ¿¬±¸¸¦ ÅëÇØ Ä¸»çÀ̽Å, ¾ËÆÄ-¸®Æ÷»ê, µµÆ÷¿ë Ŭ·Î³ªÁ¦ÆÊ, Àü½ÅÀû Ŭ·Î³ªÁ¦ÆÊÀÌ ±¸°­ÀÛ¿­°¨ÁõÈıº Áõ»óÀÇ °¨¼Ò¿¡ È¿°úÀûÀÓÀÌ º¸°íµÇ¾ú´Ù. ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ±¸°­ÀÛ¿­°¨ÁõÈıº ȯÀÚ¿¡°Ô Àü½ÅÀû Ŭ·Î³ªÁ¦ÆÊÀ» Åõ¿©ÇÏ¿© Ä¡·á È¿°ú¸¦ Æò°¡ÇÏ°í ¾àÁ¦ÀÇ È¿´É°ú ¿¬·É, ÅëÁõÀÇ °­µµ, ÅëÁõÀÇ ±â°£, °ú°ÅÀÇ Ä¡°úº´·Â, ±¸°­Á¡¸· »óÅ µîÀÇ ´Ù¾çÇÑ ÀÓ»óÀû Ư¡°úÀÇ °ü°è¸¦ ¹àÈ÷´Â °ÍÀÌ´Ù. ÀÌ ¿¬±¸´Â 2011³â 1¿ù°ú 2012³â 8¿ù »çÀÌ¿¡ ±¸°­ÀÛ¿­°¨ÁõÈıºÀ¸·Î Áø´ÜµÈ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÈÄÇâÀû ÀÓ»óÀÚ·á ºÐ¼®À» ÅëÇØ ÀÌ·ç¾îÁ³´Ù. ȯÀڵ鿡°Ô 0.5mg Ŭ·Î³ªÁ¦ÆÊÀ» ÇÏ·ç 2ȸ ó¹æÇÏ¿´´Ù. ÅëÁõÀº Àü½ÅÀû Ŭ·Î³ªÁ¦ÆÊÀÇ Åõ¿© Àü°ú Åõ¿© 1-2ÁÖ ÈÄ¿¡ 11-Á¡ ¼ýÀÚµî±Þôµµ(11-point numeric rating scale, NRS)¸¦ ÅëÇØ ÃøÁ¤µÇ¾ú´Ù. Ŭ·Î³ªÁ¦ÆÊÀÇ È¿´ÉÀº ȯÀÚÀÇ ¿¬·É, Ãʱâ ÅëÁõ °­µµ, ÅëÁõ Áö¼Ó±â°£, À¯¹ßÀÎÀÚÀÇ Á¸ÀçÀ¯¹«, ÇôÀÇ »óÅÂ, ÀÇÄ¡Âø¿ë À¯¹«¿¡ µû¶ó Æò°¡µÇ¾ú´Ù. ÃÑ 50¸íÀÇ È¯ÀÚ(¿©¼º 46¸í, ³²¼º 4¸í)°¡ ¿¬±¸¿¡ Âü¿©ÇÏ¿´´Ù. ȯÀÚµéÀº »ó±âÀÇ ÀÓ»óÀû Ư¡¿¡ µû¶ó 2-3°³ÀÇ ±ºÀ¸·Î ³ª´©¾ú´Ù. °­ÇÑ Ãʱâ ÅëÁõ ȯÀÚµéÀÇ Æò±Õ NRS °¨¼Ò·®Àº ÀÎ ¹Ý¸é¿¡ °æµµ ȤÀº Áߵ Ãʱâ ÅëÁõ ȯÀÚµéÀÇ Æò±Õ NRS °¨¼Ò·®Àº ¿´´Ù. 70¼¼ ÀÌ»óÀÇ °¡Àå ³ôÀº ¿¬·ÉÀÇ È¯ÀÚ±ºÀÇ Æò±Õ NRS °¨¼Ò·®Àº ¿´À¸¸ç, 60¼¼ ÀÌÇÏ È¯ÀÚ±º¿¡¼­´Â , 60¼¼¿¡¼­ 70¼¼ »çÀÌ È¯ÀÚ±º¿¡¼­´Â ÀÇ °¨¼Ò·®À» º¸¿´´Ù. °á·ÐÀûÀ¸·Î ³ôÀº ¿¬·ÉÀÇ È¯ÀÚµé°ú °­ÇÑ Ãʱâ ÅëÁõÀ» °¡Áø ȯÀڵ鿡°Ô¼­ Ŭ·Î³ªÁ¦ÆÊÀÇ È¿´ÉÀÌ ¶Ù¾î³­ °æÇâÀÌ ÀÖ´Ù. ±×·¯³ª ÅëÁõ ±â°£, À¯¹ßÀÎÀÚ À¯¹«, ¿­±¸¼³ À¯¹«, ÀÇÄ¡ ÀåÂø À¯¹«¿¡ ÀÇÇÑ Å¬·Î³ªÁ¦ÆÊÀÇ È¿´ÉÀÇ Â÷ÀÌ´Â Åë°èÇÐÀû À¯ÀǼºÀÌ ¾ø¾ú´Ù.

Burning mouth syndrome(BMS) is defined as chronic, painful burning sensation in the oral mucosa. Treatments for BMS include medication and psychiatric interventions. Capsaicin, alpha-lipoic acid, and topical and systemic clonazepam showed more effective in reducing the symptoms of BMS in the previous studies. The purpose of this study is to evaluate of the therapeutic efficacy of systemic clonazepam in BMS and to elucidate the relationships between such a efficacy and various clinical features, including age, pain intensity, pain duration, previous dental history and condition of oral mucosa. A retrospective clinical records audit was performed of patients diagnosed with BMS between January 2011 and August 2012. Patients were prescribed 0.5 mg clonazepam two times daily. Pain was assessed by patients on an 11-point numeric rating scale (NRS; 0 to 10) before and 1-2 weeks after systemic administration of clonazepam. The efficacy of clonazepam was evaluated in terms of patient¡¯s age, initial pain intensity, pain duration, presence or absence of precipitating event, condition of the tongue, presence or absence of denture. A total of 50 patients (46 women, 4 men) were included in this study. The patients were divided into two or three groups according to above clinical features. The amount of mean NRS reduction in patients with severe initial pain was , whereas that in patients with mild initial pain was . The amount of mean NRS reduction in oldest patients was (70yrs), and those in another younger patients were (< 60yrs) and (60yrs age < 70yrs), respectively. It was concluded that the older patients and the patients with higher intensity of initial pain tend to show better efficacy of clonazepam. However, There were no statistically significant differences according to pain duration, presence or absence of precipitating events, tongue fissuring, and wearing dentures.

Å°¿öµå

±¸°­ÀÛ¿­°¨ÁõÈıº; Ŭ·Î³ªÁ¦ÆÊ
Burning mouth syndrome; clonazepam

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI